ClinicalTrials.gg
Active, not recruitingNCT05132582HER2CLIMB-05Updated Sep 29, 2026Results posted

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

A Phase 3 interventional study of Tucatinib and Trastuzumab in HER2 Positive Breast Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Active, not recruiting at 307 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Updated Sep 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
654
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.

Enrollment
3rd of 31
654 · median 41
Started
2022
with 4 others
Phase 3
3 of 31
none open now
Primary completion
2025-09
later than 5 of 18 live
Registered
19th of 31
by date
Lead sponsor
4 of 31
Seagen, a wholly owned subsidiary of Pfizer

Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 5 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 5 of the 18 other live ones, and was the 19th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tucatinib

tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing tucatinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.

Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).

In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in.

All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.

Read the detailed description

Control arm: Placebo given orally twice daily plus trastuzumab and pertuzumab every 21 days

Experimental arm: Tucatinib 300 mg given orally twice daily plus trastuzumab and pertuzumab every 21 days

Trastuzumab and pertuzumab will be administered as follows:

  • Trastuzumab will be given intravenously (IV) at a dose of 6 mg/kg or subcutaneously (SC) at a fixed dose of 600 mg, once every 21 days.

AND

  • Pertuzumab will be given IV at 420 mg every 21 days. OR
  • Fixed dose combination of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given SC, once every 21 days, in lieu of trastuzumab and pertuzumab individually.
03

Conditions studied

  • HER2 Positive Breast Cancer

Browse trials for

Keywords

  • HER2+ breast cancer
  • Breast Cancer
  • Metastatic breast cancer
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Centrally confirmed + breast carcinoma according to the 2018 American Society of Clinical Oncologists (ASCO) College of American Pathologists (CAP) guidelines prior to randomization (defined as a 3+ score on immunohistochemistry (IHC) and/or 2+ IHC and concurrent positive by ISH).
  • Have unresectable locally advanced or disease.

    • If recurrent (after [neo] therapy), must be at least 6 month treatment free from any trastuzumab and pertuzumab received in the early breast cancer setting for advanced HER2+ disease.
  • Have received 4-8 cycles of pre-study induction therapy including only trastuzumab, pertuzumab, and taxane as of therapy for the treatment of advanced breast cancer prior to study enrollment. Participants are eligible provided they are without evidence of disease progression following completion of induction therapy.
  • Known hormone receptor status (per local guidelines; may be hormone receptor positive [HR+] or negative [HR-])
  • (ECOG) Performance Status of 0 or 1
  • CNS Inclusion - Based on screening contrast-enhanced brain magnetic resonance imaging (MRI), participants may have any of the following:

    • No evidence of
    • Untreated brain metastases which are asymptomatic not needing immediate local treatment and, if identified on prior brain imaging, without evidence of progression since starting first-line induction therapy with trastuzumab, pertuzumab, and taxane
    • Previously treated brain metastases which are asymptomatic

      • Brain metastases previously treated with local therapy must not have progressed since treatment

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any tyrosine kinase inhibitor targeting and/or epidermal growth factor receptor (EGFR) including pyrotinib, lapatinib, tucatinib, neratinib, and afatinib (except neratinib if given in extended setting and ≥ 12 months have elapsed since last neratinib dose prior to start of study drug)
  • Unable to undergo contrast-enhanced MRI of the brain
  • CNS Exclusion - Based on screening brain MRI and clinical assessment

    • Symptomatic after CNS-directed local therapy
    • Progression of brain metastases since starting trastuzumab, pertuzumab, and taxane
    • Ongoing use of systemic at a total daily dose of >2 mg of dexamethasone (or equivalent)
    • Any untreated brain lesion in an anatomic site which may pose risk to participant
    • Known or suspected (LMD)
    • Poorly controlled (>1/week) seizures, or other persistent neurologic symptoms
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
654 participants (actual)

Study arms

  • Experimental
    Tucatinib + trastuzumab + pertuzumab

    Tucatinib + trastuzumab + pertuzumab

    Drug: Tucatinib · Drug: Trastuzumab · Drug: Pertuzumab · Drug: Combination product: Trastuzumab + Pertuzumab

  • Active comparator
    Placebo + trastuzumab + pertuzumab

    Placebo + trastuzumab + pertuzumab

    Drug: Trastuzumab · Drug: Pertuzumab · Drug: Combination product: Trastuzumab + Pertuzumab · Drug: Placebo

Interventions

  • 300mg given by mouth (orally) twice daily

    Also known as: TUKYSA, ONT-380, ARRY-380

  • 6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days

    Also known as: Herceptin, Herceptin Hylecta

  • 420mg given by IV every 21 days

    Also known as: Perjeta

  • DrugCombination product: Trastuzumab + Pertuzumab

    Drug pages: Trastuzumab · Pertuzumab

    600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.

    Also known as: Phesgo

  • DrugPlacebo

    Given orally twice daily

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

    PFS: time from randomization to the first documented disease progression (PD) (as assessed by investigator per RECIST 1.1) or death from any cause, whichever occurred first. PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum of diameter recorded since the treatment started or the appearance of 1 or more new lesions. Participants without documentation of PD/ death at the time of analysis, were censored at date of last tumor assessment with an overall response of complete response (CR), partial response (PR), stable disease (SD), non-CR/non-PD or no evidence of disease (NED). CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.

    Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS: time from randomization to death due to any cause. For a participant who would not known to have died by the end of study follow-up, observation of OS would be censored on the date the participant was last known to be alive (i.e., the date of last contact).

    Time frame: From the date of randomization until date of death or censoring date (approximately 66.7 months)

  2. PFS as Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1

    PFS per BICR was defined as the time from the date of randomization to the documented disease progression assessed by BICR according to RECIST v1.1 or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>=20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.

    Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)

  3. Time to Deterioration (TTD) of Health-Related Quality of Life (HRQoL)

    Time to deterioration of HRQoL was defined as time to 10-point decrease in the global health status/QoL scale of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30). EORTC QLQ-C30 is 30 item questionnaires composed of 5 multi-item functional domains (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, nausea, and vomiting) and 6 single items for symptoms (shortness of breath, loss of appetite, sleep disturbance, constipation, diarrhea and financial impact of the disease), 2 global items (health, overall QoL). Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms.

    Time frame: Approximately 66.7 months

  4. Central Nervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1

    CNS-PFS was defined as the time from randomization to investigator assessed disease progression in brain according to RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>= 20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since the treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death at the time of analysis were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.

    Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both Serious AE (SAEs) and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months)

  6. Number of Participants With Treatment Emergent Laboratory Abnormalities

    TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Treatment emergent laboratory abnormalities include: hematology (hemoglobin decreased, hemoglobin increased, leukocytes decreased, neutrophils decreased, platelets decreased); chemistry (alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, creatinine increased, potassium decreased, potassium increased, sodium decreased, sodium increased, total bilirubin increased).

    Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

  7. Number of Participants With TEAEs Leading to Dose Discontinuations

    TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose discontinuations with study treatment will be reported.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

  8. Number of Participants With TEAEs Leading to Dose Hold

    TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose hold with study treatment will be reported. Dose hold requirements are defined per protocol.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

  9. Number of Participants With TEAEs Leading to Dose Reductions

    TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose reductions with tucatinib, trastuzumab and pertuzumab are reported. Dose reduction requirements are defined per protocol.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

  10. Trough Concentration (Ctrough) of Tucatinib

    Concentration at Trough was defined as predose/trough concentration observed directly from data.

    Time frame: Pre-dose on Day 1 of Cycles 2, 3, 4, 5 and 6

Other outcomes

  1. Number of Participants With TEAEs: Through Study Completion

    An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both SAEs and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

    Time frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

07

Results

Posted Sep 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
Started326328
Intent-to-treat (itt) analysis set326328
Safety analysis set (sas)326324
Completed00
Not completed326328
Withdrew: Death1833
Withdrew: Withdrawal by subject94
Withdrew: Ongoing299291

Outcome measures

PrimaryProgression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

PFS: time from randomization to the first documented disease progression (PD) (as assessed by investigator per RECIST 1.1) or death from any cause, whichever occurred first. PD: \>=20% increase in sum of diameters of target lesions, taking as reference the smallest sum of diameter recorded since the treatment started or the appearance of 1 or more new lesions. Participants without documentation of PD/ death at the time of analysis, were censored at date of last tumor assessment with an overall response of complete response (CR), partial response (PR), stable disease (SD), non-CR/non-PD or no evidence of disease (NED). CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.

Time frame:
From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
MonthsTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.124.9 (21.3 to NA)16.3 (12.6 to 18.7)
Statistical analysis
  • Tucatinib + Trastuzumab + Pertuzumab vs Placebo + Trastuzumab + Pertuzumab · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.641 · 95% CI 0.514 to 0.799Hazard ratio was calculated based on stratified Cox proportional hazards model.
SecondaryOverall Survival (OS)

OS: time from randomization to death due to any cause. For a participant who would not known to have died by the end of study follow-up, observation of OS would be censored on the date the participant was last known to be alive (i.e., the date of last contact).

Time frame:
From the date of randomization until date of death or censoring date (approximately 66.7 months)

Results for this outcome have not been posted.

SecondaryPFS as Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1

PFS per BICR was defined as the time from the date of randomization to the documented disease progression assessed by BICR according to RECIST v1.1 or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>=20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.

Time frame:
From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Reported as:
Median · Months
PFS as Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1
MonthsTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
PFS as Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.128.9 (24.3 to NA)16.0 (12.3 to 22.9)
Statistical analysis
  • Tucatinib + Trastuzumab + Pertuzumab vs Placebo + Trastuzumab + Pertuzumab · Log Rank · p = 0.0004 · Hazard ratio (hr): 0.654 · 95% CI 0.517 to 0.828Hazard ratio was calculated based on stratified Cox proportional hazards model.
SecondaryTime to Deterioration (TTD) of Health-Related Quality of Life (HRQoL)

Time to deterioration of HRQoL was defined as time to 10-point decrease in the global health status/QoL scale of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30). EORTC QLQ-C30 is 30 item questionnaires composed of 5 multi-item functional domains (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, nausea, and vomiting) and 6 single items for symptoms (shortness of breath, loss of appetite, sleep disturbance, constipation, diarrhea and financial impact of the disease), 2 global items (health, overall QoL). Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms.

Time frame:
Approximately 66.7 months

Results for this outcome have not been posted.

SecondaryCentral Nervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1

CNS-PFS was defined as the time from randomization to investigator assessed disease progression in brain according to RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, PD: \>= 20% increase in sum of diameter of target lesions, taking as reference the smallest sum of diameters recorded since the treatment started or appearance of 1 or more new lesions, unequivocal progression of existing non-target lesions. Participants without documentation of PD/ death at the time of analysis were censored at date of last tumor assessment with an overall response of CR, PR, SD, non-CR/non-PD or NED. CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameter since the treatment started. Kaplan-Meier method was used for analysis.

Time frame:
From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Reported as:
Median · Months
Central Nervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1
MonthsTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
Central Nervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Tucatinib + Trastuzumab + Pertuzumab vs Placebo + Trastuzumab + Pertuzumab · Log Rank · p = 0.3041 · Hazard ratio (hr): 0.846 · 95% CI 0.616 to 1.162Hazard ratio was calculated based on stratified Cox proportional hazards model.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both Serious AE (SAEs) and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
Number of Participants With Treatment Emergent Adverse Events (TEAEs)323313
SecondaryNumber of Participants With Treatment Emergent Laboratory Abnormalities

TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Treatment emergent laboratory abnormalities include: hematology (hemoglobin decreased, hemoglobin increased, leukocytes decreased, neutrophils decreased, platelets decreased); chemistry (alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, creatinine increased, potassium decreased, potassium increased, sodium decreased, sodium increased, total bilirubin increased).

Time frame:
From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs Leading to Dose Discontinuations

TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose discontinuations with study treatment will be reported.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs Leading to Dose Hold

TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose hold with study treatment will be reported. Dose hold requirements are defined per protocol.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With TEAEs Leading to Dose Reductions

TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. In this outcome measure, number of participants with TEAEs leading to dose reductions with tucatinib, trastuzumab and pertuzumab are reported. Dose reduction requirements are defined per protocol.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

Results for this outcome have not been posted.

SecondaryTrough Concentration (Ctrough) of Tucatinib

Concentration at Trough was defined as predose/trough concentration observed directly from data.

Time frame:
Pre-dose on Day 1 of Cycles 2, 3, 4, 5 and 6
Reported as:
Geometric mean · nanograms per milliliter
Trough Concentration (Ctrough) of Tucatinib
nanograms per milliliterTucatinib + Trastuzumab + Pertuzumab
Cycle 2151.83 ± 180.04
Cycle 3158.63 ± 144.77
Cycle 4137.0 ± 192.19
Cycle 5155.4 ± 180.92
Cycle 6146.03 ± 215.17
Other pre-specifiedNumber of Participants With TEAEs: Through Study Completion

An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both SAEs and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.

Time frame:
From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tucatinib + Trastuzumab + Pertuzumab18/326 (5.5%)55/326 (16.9%)323/326 (99.1%)
Placebo + Trastuzumab + Pertuzumab33/328 (10.1%)26/324 (8%)313/324 (96.6%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
Alanine aminotransferase increasedInvestigations5/3260/324
Drug-induced liver injuryHepatobiliary disorders4/3260/324
DiarrhoeaGastrointestinal disorders3/3260/324
Urinary tract infectionInfections and infestations0/3262/324
Wound infectionInfections and infestations0/3262/324
SeizureNervous system disorders1/3262/324
Cardiac failureCardiac disorders2/3261/324
Liver injuryHepatobiliary disorders2/3260/324
BacteraemiaInfections and infestations2/3260/324
CellulitisInfections and infestations2/3261/324
Most frequent other events
Showing 10 of 118
Most frequent other events
EventTucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + Pertuzumab
DiarrhoeaGastrointestinal disorders237/326166/324
NauseaGastrointestinal disorders107/32676/324
Alanine aminotransferase increasedInvestigations90/32623/324
Aspartate aminotransferase increasedInvestigations82/32629/324
ArthralgiaMusculoskeletal and connective tissue disorders67/32675/324
FatigueGeneral disorders67/32641/324
VomitingGastrointestinal disorders64/32645/324
PruritusSkin and subcutaneous tissue disorders62/32658/324
HeadacheNervous system disorders61/32657/324
CoughRespiratory, thoracic and mediastinal disorders60/32645/324

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + PertuzumabTotal
Mean53.2 ± 11.553.2 ± 11.053.2 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Tucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + PertuzumabTotal
Female326328654
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + PertuzumabTotal
White147147294
Asian119111230
Not reportable394079
Black or African American10919
Other5813
Unknown167
Multiple516
American Indian or Alaska Native044
Native Hawaiian or Other Pacific Islander022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tucatinib + Trastuzumab + PertuzumabPlacebo + Trastuzumab + PertuzumabTotal
Not Hispanic, Latino/a, or of Spanish Origin221212433
Hispanic, Latino/a, or of Spanish Origin5571126
Not reportable394180
Unknown11415
08

Study locations

307 sites

Showing the first 100 of 307 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dieras V, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard MF, Jerzak KJ, Hu X, Martins de Aquino Pimentel LC, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Jacot W, Sohn J, Cronemberger Silva E, Mueller V, Yang S, Granata G, Shen Q, Santarpia L, Hamilton E; HER2CLIMB-05 Investigators. HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. J Clin Oncol. 2026 Jun 10;44(17):1597-1607. doi: 10.1200/JCO-25-02600. Epub 2025 Dec 10. PubMed 41369677 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Sep 2025, 41 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 41 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 24, 2021
StartActual
Mar 7, 2022
Primary completionActual
Sep 5, 2025
CompletionEst.
Sep 28, 2027
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression-free survivalFree Survival (PFS) as Assessed by investigator assessment perInvestigator Per Response Evaluation Criteria in Solid Tumors (RECIST) v1Version (v) 1.1Time frame: Up to approximately 3 years → From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Sep 29, 2026
Documents
Secondary outcomes
7 edited, 4 added, 4 removed
What changed in the outcomes
  • EditedOverall survivalSurvival (OS)Time frame: Up to approximately 5 years → From the date of randomization until date of death or censoring date (approximately 66.7 months)
  • EditedPFS as Assessed by blinded independent central reviewBlinded Independent Central Review (BICR) perPer RECIST v1.1Time frame: Up to approximately 3 years → From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
  • EditedTime to deteriorationDeterioration (TTD) of healthHealth-related qualityRelated Quality of lifeLife (HRQoL)Time frame: Up to approximately 3 years → Approximately 66.7 months
  • EditedCentral nervous systemNervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1Time frame: Up to approximately 3 years → From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
  • EditedIncidenceNumber of adverse eventsParticipants With Treatment Emergent Adverse Events (AEsTEAEs)Time frame: Through 30 days after last study treatment, approximately 18 months → From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months)
  • EditedIncidenceNumber of laboratory abnormalitiesParticipants With Treatment Emergent Laboratory AbnormalitiesTime frame: Through 30 days after last study treatment, approximately 18 months → From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
  • EditedMaximum concentrationTrough Concentration (CmaxCtrough) of TucatinibTime frame: Through 30 days after last study treatment, approximately 18 months → Pre-dose on Day 1 of Cycles 2, 3, 4, 5 and 6
  • AddedNumber of Participants With TEAEs Leading to Dose DiscontinuationsTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
  • AddedNumber of Participants With TEAEs Leading to Dose HoldTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
  • AddedNumber of Participants With TEAEs Leading to Dose ReductionsTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
  • RemovedIncidence of tucatinib dose alterationsTime frame: Through 30 days after last study treatment, approximately 18 months
  • RemovedIncidence of trastuzumab dose alterationsTime frame: Through 30 days after last study treatment, approximately 18 months
  • RemovedIncidence of pertuzumab dose alterationsTime frame: Through 30 days after last study treatment, approximately 18 months
  • RemovedTrough concentration (Ctrough)Time frame: Through 30 days after last study treatment, approximately 18 months
  • Addedother outcomeNumber of Participants With TEAEs: Through Study CompletionTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression-free survivalFree Survival (PFS) as Assessed by investigator assessment perInvestigator Per Response Evaluation Criteria in Solid Tumors (RECIST) v1Version (v) 1.1Time frame: Up to approximately 3 years → From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
    Secondary outcomes 7 edited, 4 added, 4 removed
    What changed in the outcomes
    • EditedOverall survivalSurvival (OS)Time frame: Up to approximately 5 years → From the date of randomization until date of death or censoring date (approximately 66.7 months)
    • EditedPFS as Assessed by blinded independent central reviewBlinded Independent Central Review (BICR) perPer RECIST v1.1Time frame: Up to approximately 3 years → From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
    • EditedTime to deteriorationDeterioration (TTD) of healthHealth-related qualityRelated Quality of lifeLife (HRQoL)Time frame: Up to approximately 3 years → Approximately 66.7 months
    • EditedCentral nervous systemNervous System (CNS) PFS as Assessed by Investigator Per RECIST v1.1Time frame: Up to approximately 3 years → From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
    • EditedIncidenceNumber of adverse eventsParticipants With Treatment Emergent Adverse Events (AEsTEAEs)Time frame: Through 30 days after last study treatment, approximately 18 months → From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 42.3 months)
    • EditedIncidenceNumber of laboratory abnormalitiesParticipants With Treatment Emergent Laboratory AbnormalitiesTime frame: Through 30 days after last study treatment, approximately 18 months → From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
    • EditedMaximum concentrationTrough Concentration (CmaxCtrough) of TucatinibTime frame: Through 30 days after last study treatment, approximately 18 months → Pre-dose on Day 1 of Cycles 2, 3, 4, 5 and 6
    • AddedNumber of Participants With TEAEs Leading to Dose DiscontinuationsTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
    • AddedNumber of Participants With TEAEs Leading to Dose HoldTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
    • AddedNumber of Participants With TEAEs Leading to Dose ReductionsTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
    • RemovedIncidence of tucatinib dose alterationsTime frame: Through 30 days after last study treatment, approximately 18 months
    • RemovedIncidence of trastuzumab dose alterationsTime frame: Through 30 days after last study treatment, approximately 18 months
    • RemovedIncidence of pertuzumab dose alterationsTime frame: Through 30 days after last study treatment, approximately 18 months
    • RemovedTrough concentration (Ctrough)Time frame: Through 30 days after last study treatment, approximately 18 months
    • Addedother outcomeNumber of Participants With TEAEs: Through Study CompletionTime frame: From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05132582
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Mar 7, 2022
Primary completion
Sep 5, 2025
Completion
Sep 28, 2027 (estimated)
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion